Overcoming Multidrug Resistance in Cancer Cells

Strategic Insights -

Researchers from Northeastern University have made significant advancements in overcoming multidrug resistance in cancer cells using a combination of gene silencing and nanoparticle-mediated delivery of paclitaxel. The study, published in Cancer Chemotherapy and Pharmacology in 2009, demonstrates the efficacy of this approach in treating refractory tumors. By silencing the MDR-1 gene, which is responsible for multidrug resistance, and delivering paclitaxel through biodegradable polymeric nanoparticles, the researchers achieved a significant enhancement in cytotoxic activity against multidrug-resistant SKOV3(TR) human ovarian adenocarcinoma cells.

Key Takeaways:

  • The study examined the effect of MDR-1 gene silencing using siRNA and paclitaxel co-therapy in overcoming tumor multidrug resistance.
  • Poly(ethylene oxide)-modified poly(beta-amino ester) and PEO-modified poly(epsilon-caprolactone) nanoparticles were formulated to efficiently encapsulate MDR-1 silencing siRNA and PTX, respectively.
  • SiRNA-mediated MDR-1 gene silencing was evident at 100 nM dose in SKOV3(TR) human ovarian adenocarcinoma cells.
  • The combination of MDR-1 gene silencing and nanoparticle-mediated delivery significantly influenced the cytotoxic activity of PTX in SKOV3TR cells.
  • The enhancement in cytotoxicity was speculated to be due to an increase in intracellular drug accumulation upon MDR-1 gene silencing leading to an apoptotic cell-kill effect.
  • This preliminary result is highly encouraging for the development of combination nano-therapeutic strategies that combine gene silencing and drug delivery.
  • S. Yadav and colleagues from Northeastern University conducted the study, in collaboration with other researchers (see also Ovarian Cancer).
  • The study contributes to the understanding of combination with gene silencing and nano-therapy for cancer treatments.

Statistics:

  • 100 nM dose of siRNA was used to silence MDR-1 gene in SKOV3(TR) human ovarian adenocarcinoma cells.
  • Combination of MDR-1 gene silencing and nanoparticle-mediated delivery was found to significantly influence the cytotoxic activity of PTX in SKOV3TR cells.

Sources:

  • Yadav, S., et al. "Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells." Cancer Chemotherapy and Pharmacology, vol. 63, no. 4, 2009, pp. 711-722.
  • Gene Therapy Weekly, "Gene silencing and nanoparticle delivery enhance paclitaxel cytotoxicity in multidrug-resistant cancer cells."